Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease (ILD) with unknown etiology in which gradual fibrotic scarring of the lungs leads to usual interstitial pneumonia (UIP) and, ultimately, to death. IPF affects three million people worldwide, and the only currently available treatments include the antifibrotic drugs nintedanib and pirfenidone, which effectively reduce fibrosis progression are, unfortunately, not effective in curing the disease. In recent years, the paradigm of IPF pathogenesis has shifted from a fibroblast-driven disease to an epithelium-driven disease, wherein, upon recurrent microinjuries, dysfunctional alveolar type II epithelial cells (ATII) are not only unable to sustain physiological lung regeneration but also promote aberrant epithelial–mesenchymal crosstalk. This creates a drift towards fibrosis rather than regeneration. In the context of this review article, we discuss the most relevant mechanisms involved in IPF pathogenesis with a specific focus on the role of dysfunctional ATII cells in promoting disease progression. In particular, we summarize the main causes of ATII cell dysfunction, such as aging, environmental factors, and genetic determinants. Next, we describe the known mechanisms of physiological lung regeneration by drawing a parallel between embryonic lung development and the known pathways involved in ATII-driven alveolar re-epithelization after injury. Finally, we review the most relevant interventional clinical trials performed in the last 20 years with the aim of underlining the urgency of developing new therapies against IPF that are not only aimed at reducing disease progression by hampering ECM deposition but also boost the physiological processes of ATII-driven alveolar regeneration.
Although gene alterations of the RAS/RAF/MEK/ERK pathway are uncommon in breast cancer, this pathway is frequently activated in breast tumors, implying its role in tumor progression. We describe, after a revision of the literature, the frequency and types of gene alterations affecting this pathway in breast cancer by analyzing some public datasets from cBioPortal. Moreover, we consider their prognostic and predictive impact on treatment response, along with the role of transcriptomic predictors of RAS pathway activation. Our analysis shows that the driver alterations in RAS/RAF/MEK/ERK pathway-related genes are detected in 11% of primary breast cancers. The most frequently mutated genes are NF1 and KRAS, while copy number alterations mainly affect KRAS and BRAF, especially in basal-like tumors. The subgroup of patients carrying these alterations shows a worse prognosis; alterations in NF1 and RAF1 are associated with significantly reduced breast-cancer-specific survival in multivariate analysis. The literature review shows that the pathway is implicated, either by genetic or epigenetic alterations or by signaling network adaptations, in the mechanisms of sensitivity and resistance to a wide range of drugs used in the treatment of breast cancer. A thorough understanding of these alterations is critical for developing combination therapies that can delay or overcome drug resistance.
Alveolar type II (ATIIs) to ATI cell trans-differentiation is an essential physiological process for effective alveolar repair after damage. In idiopathic pulmonary fibrosis (IPF) ATIIs are damaged and therefore cannot trans-differentiate ATIs, contributing to the progressive lung function damage. Available treatments for IPF patients, Nintedanib and Pirfenidone only reduce the progressive fibrotic scarring of the lungs, without curing the disease by stimulating the endogenous regenerative pathways. ATIIs represent a relevant target for the development of new pro-regenerative therapies for the lung. We performed a cell-based HTS assay on 2042 human microRNA mimics for their efficacy in regulating alveolar repair by promoting ATII to ATI trans-differentiation in primary mouse ATIIs. We identified 7 miRNAs increasing and 4 miRNAs reducing this process. With a translational perspective, we also validated 2 of these microRNAs in primary mouse fibroblasts, to evaluate their potential anti-fibrotic effect, in adenocarcinoma cell line (A549) to exclude any miRNA-induce tumorigenic effect, and in hepatocarcinoma cell line (HepG2), to exclude liver toxicity. Finally, we delivered the selected 2 microRNAs in a bleomycin-induced lung fibrosis mouse model using both viral (rAAV-6.2-FF) miRNA-delivery strategy to specifically target ATII cells or naked microRNAs to evaluate their efficacy in reducing lung fibrosis and promoting alveolar regeneration. We successfully identified 1 microRNA able to 1) promote ATII to ATI trans-differentiation in vitro 2) reduce fibroblasts activation 3) prevent and revert induced-lung fibrosis in mice, promoting alveolar regeneration.
Alveolar type II (ATIIs) to ATI cell trans-differentiation is an essential physiological process for effective alveolar repair after damage. In idiopathic pulmonary fibrosis (IPF) ATIIs are damaged and therefore cannot trans-differentiate ATIs, contributing to the progressive lung function damage. Available treatments for IPF patients, Nintedanib and Pirfenidone only reduce the progressive fibrotic scarring of the lungs, without curing the disease by stimulating the endogenous regenerative pathways. ATIIs represent a relevant target for the development of new pro-regenerative therapies for the lung. We performed a cell-based HTS assay on 2042 human microRNA mimics for their efficacy in regulating alveolar repair by promoting ATII to ATI trans-differentiation in primary mouse ATIIs. We identified 7 miRNAs increasing and 4 miRNAs reducing this process. With a translational perspective, we also validated 2 of these microRNAs in primary mouse fibroblasts, to evaluate their potential anti-fibrotic effect, in adenocarcinoma cell line (A549) to exclude any miRNA-induce tumorigenic effect, and in hepatocarcinoma cell line (HepG2), to exclude liver toxicity. Finally, we delivered the selected 2 microRNAs in a bleomycin-induced lung fibrosis mouse model using both viral (rAAV-6.2-FF) miRNA-delivery strategy to specifically target ATII cells or naked microRNAs to evaluate their efficacy in reducing lung fibrosis and promoting alveolar regeneration. We successfully identified 1 microRNA able to 1) promote ATII to ATI trans-differentiation in vitro 2) reduce fibroblasts activation 3) prevent and revert induced-lung fibrosis in mice, promoting alveolar regeneration.